Research is now closing in on novel molecular targets for cervical cancer therapeutics, including the utilization of epidermal growth factor receptor (EGFR) antagonists, such as panitumumab, and multitargeted tyrosine kinase inhibitors, such as imatinib and sunitinib (Candelaria et al., 2009; Duenasgonzalez et al., 2014). Here, EGFR is linked to cervical carcinoma.